Elmer Antileo

Led IVDR transition for CyFlow GainSet beads, delivering regulatory and technical documentation aligned with EU requirements. Milestones included Intended Purpose, DHF documentation, risk analysis, IFU creation, design review, test plan/report, ensuring timely market readiness. Managed antibody product portfolio, including development, discontinuation, and analytical performance testing, optimizing portfolio alignment with customer needs. Developed strategic market and SWOT analysis for new product proposal

• Coordinated and supervised COVID-19 study: Adaptive immune response after COVID-19 vaccination in healthy volunteers. • Established a Corona Multiplex Assay utilizing endemic human coronaviruses, mutant variants, spike protein, and spike protein domains. • Evaluation of the neuroprotective effects of Alanyl-Aminopeptidase (APN) inhibition during neuroinflammation: Wnt signaling pathway as key modulator in APN inhibition.